"In particular, his experience in UK-based telehealth and partnering with the NHS will be invaluable as ResApp expands its footprint into Europe."
It seems to me this appointment is strategically targeted for penetration into the UK NHS market. Dr Stein's appointment is preceded by an establishment of RAP wholly owned UK-based subsidiary barely a month ago.
I suspect RAP first contract outside Australia will be in the UK.
RAP Price at posting:
18.5¢ Sentiment: Buy Disclosure: Held